Skip to main content
JUPITER NEUROSCIENCES, INC. logo

JUPITER NEUROSCIENCES, INC. — Investor Relations & Filings

Ticker · JUNS ISIN · US48208B2034 US Manufacturing
Open in API
Filings indexed 146 across all filing types
Latest filing 2026-06-05 Board/Management Inform…
Country US United States of America
Listing US JUNS

About JUPITER NEUROSCIENCES, INC.

https://jupiterneurosciences.com/

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neuroinflammation, central nervous system (CNS) disorders, and rare diseases. The company's core technology is a unique resveratrol-based platform. Its flagship product candidate, JOTROL™, is an oral formulation of resveratrol designed to address neuroinflammation and oxidative stress. The therapeutic pipeline targets a range of conditions, including neurodegenerative and rare diseases, aiming to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
424B3
Board/Management Information Classification · 88% confidence The document is a SEC Form 8-K (filed as an exhibit to a 424B3 prospectus supplement) whose primary substantive item is Item 5.02: the appointment of a new Chief Operating Officer and President and associated compensatory arrangements, along with director and executive option grants. This constitutes an announcement of changes in senior management and their compensation. Therefore, it falls squarely under Board/Management Information (MANG).
2026-06-05 English
8-K
Board/Management Information Classification · 91% confidence The document is a U.S. SEC Form 8-K ‘Current Report’ under Item 5.02, detailing the appointment of a new officer (Chief Operating Officer and President), amendments to employment agreements, and director/officer compensation arrangements. This falls under announcements of changes in senior management and related compensatory arrangements, which corresponds to Board/Management Information (MANG).
2026-06-05 English
424B3
Capital/Financing Update Classification · 93% confidence The document is a prospectus supplement (Rule 424(b)(3)) and an attached Form 8-K current report disclosing a registered direct offering of common stock, a Securities Purchase Agreement and Placement Agent Agreement. This is an update on fundraising and capital structure change (new share issuance), fitting the Capital/Financing Update category (CAP).
2026-05-21 English
424B3
Capital/Financing Update Classification · 85% confidence The document is a Form 424B3 prospectus supplement to an S-1 registration statement, updating the prospectus for a new equity offering. This is part of the company’s fundraising/capital raising process, so it falls under Capital/Financing Update (CAP).
2026-05-21 English
8-K
Regulatory Filings Classification · 86% confidence The document is a Form 8-K current report filed with the U.S. Securities and Exchange Commission, disclosing entry into a material definitive agreement (a Securities Purchase Agreement and Placement Agent Agreement) and other report exhibits. Form 8-K is a regulatory compliance filing under the Exchange Act and does not itself constitute an annual or interim financial report, earnings release, or other specialized category. Therefore it falls into the general Regulatory Filings category.
2026-05-21 English
424B5
Capital/Financing Update Classification · 90% confidence The document is a prospectus supplement filed under Rule 424(b)(5) for the offering of 7,142,858 shares of common stock at $0.28 per share, detailing the terms of the share issuance, placement agent fees, and related capital raising information. This constitutes a financing activity update rather than an annual report, governance update, or earnings release. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-21 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.